These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37155240)

  • 1. Comparing the Use of a Mobile App and a Web-Based Notification Platform for Surveillance of Adverse Events Following Influenza Immunization: Randomized Controlled Trial.
    Bota AB; Bettinger JA; Sarfo-Mensah S; Lopez J; Smith DP; Atkinson KM; Bell C; Marty K; Serhan M; Zhu DT; McCarthy AE; Wilson K
    JMIR Public Health Surveill; 2023 May; 9():e39700. PubMed ID: 37155240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of the feasibility and usability of a proof of concept mobile app for adverse event reporting post influenza vaccination.
    Wilson K; Atkinson KM; Westeinde J; Bell C; Marty K; Fergusson D; Deeks SL; Crowcroft N; Bettinger JA
    Hum Vaccin Immunother; 2016 Jul; 12(7):1738-48. PubMed ID: 26905396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of a Web-Based Platform (Trial My App) to Efficiently Conduct Randomized Controlled Trials of mHealth Apps For Patients With Cardiovascular Risk Factors: Protocol For Evaluating an mHealth App for Hypertension.
    Lokker C; Jezrawi R; Gabizon I; Varughese J; Brown M; Trottier D; Alvarez E; Schwalm JD; McGillion M; Ma J; Bhagirath V
    JMIR Res Protoc; 2021 Feb; 10(2):e26155. PubMed ID: 33522978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmarketing Safety Monitoring After Influenza Vaccination Using a Mobile Health App: Prospective Longitudinal Feasibility Study.
    Nguyen MTH; Krause G; Keller-Stanislawski B; Glöckner S; Mentzer D; Ott JJ
    JMIR Mhealth Uhealth; 2021 May; 9(5):e26289. PubMed ID: 33960950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protecting Older Adult Residents in Care Facilities Against Influenza and COVID-19 Using the Influenza Communication, Advice and Reporting (FluCARE) App: Prospective Cohort Mixed Methods Study.
    Quinn E; Hsiao KH; Johnstone T; Gomez M; Parasuraman A; Ingleton A; Hirst N; Najjar Z; Gupta L
    JMIR Form Res; 2023 Mar; 7():e38080. PubMed ID: 36763638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active surveillance for influenza vaccine adverse events: the integrated vaccine surveillance system.
    Newes-Adeyi G; Greece J; Bozeman S; Walker DK; Lewis F; Gidudu J
    Vaccine; 2012 Feb; 30(6):1050-5. PubMed ID: 22200501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.
    Moro PL; Zhang B; Ennulat C; Harris M; McVey R; Woody G; Marquez P; McNeil MM; Su JR
    Vaccine; 2023 Mar; 41(11):1859-1863. PubMed ID: 36669964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the Remote Early Detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Oct; 22(1):694. PubMed ID: 34635140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful methodology for large-scale surveillance of severe events following influenza vaccination in Canada, 2011 and 2012.
    Bettinger JA; Rouleau I; Gariepy MC; Bowie WR; Valiquette L; Vanderkooi OG; Kellner JD; Coleman BL; McNeil SA; McCarthy A; De Serres G;
    Euro Surveill; 2015 Jul; 20(29):21189. PubMed ID: 26227369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National safety surveillance of quadrivalent recombinant influenza vaccine in Taiwan during NH 20/21.
    Tsai SY; Yeh TY; Chiu NC; Huang CT
    Vaccine; 2022 Jun; 40(26):3701-3704. PubMed ID: 35577629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parental views on vaccine safety and future vaccinations of children who experienced an adverse event following routine or seasonal influenza vaccination in 2010.
    Parrella A; Gold M; Marshall H; Braunack-Mayer A; Watson M; Baghurst P
    Hum Vaccin Immunother; 2012 May; 8(5):662-7. PubMed ID: 22634441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009-2010 season in the active component U.S. military and civilians aged 17-44years reported to the Vaccine Adverse Event Reporting System.
    Bardenheier BH; Duderstadt SK; Engler RJ; McNeil MM
    Vaccine; 2016 Aug; 34(37):4406-14. PubMed ID: 27449076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smartphone app uses loyalty point incentives and push notifications to encourage influenza vaccine uptake.
    Dale LP; White L; Mitchell M; Faulkner G
    Vaccine; 2019 Jul; 37(32):4594-4600. PubMed ID: 29699784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Mobile App Leveraging Citizenship Engagement to Perform Anonymized Longitudinal Studies in the Context of COVID-19 Adverse Drug Reaction Monitoring: Development and Usability Study.
    Di Filippo M; Avellone A; Belingheri M; Paladino ME; Riva MA; Zambon A; Pescini D
    JMIR Hum Factors; 2022 Nov; 9(4):e38701. PubMed ID: 35930561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Associated With Trial Completion and Adherence in App-Based N-of-1 Trials: Protocol for a Randomized Trial Evaluating Study Duration, Notification Level, and Meaningful Engagement in the Brain Boost Study.
    Bobe JR; Buros J; Golden E; Johnson M; Jones M; Percha B; Viglizzo R; Zimmerman N
    JMIR Res Protoc; 2020 Jan; 9(1):e16362. PubMed ID: 31913135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hearing disorder following COVID-19 vaccination: A pharmacovigilance analysis using the Vaccine Adverse Event Reporting System.
    Chen C; Fu F; Ding L; Xiao J
    J Clin Pharm Ther; 2022 Nov; 47(11):1789-1795. PubMed ID: 36089844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Passive enhanced safety surveillance of GSK's quadrivalent seasonal influenza vaccine in Belgium, Germany and Spain, an observational study: protocol for the 2018/2019 influenza season.
    Dos Santos G; Yeakey A; Shende V; Smith K; Lin F; Zandman-van-Dijk E; Damaso S; Schmidt A
    BMJ Open; 2019 Aug; 9(8):e028043. PubMed ID: 31427321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Participant-Centered Online Active Surveillance for Adverse Events Following Vaccination in a Large Clinical Trial: Feasibility and Usability Study.
    Munnoch SA; Cashman P; Peel R; Attia J; Hure A; Durrheim DN
    J Med Internet Res; 2019 Oct; 21(10):e14791. PubMed ID: 31647470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of response rates on invitation mode of a web-based survey on influenza vaccine adverse events among healthcare workers: a pilot study.
    Tai X; Smith AM; McGeer AJ; Dubé E; Holness DL; Katz K; McGillis Hall L; McNeil SA; Powis J; Coleman BL
    BMC Med Res Methodol; 2018 Jun; 18(1):59. PubMed ID: 29925324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.